Literature DB >> 19075223

Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate.

Larry Pederson1, Ming Ruan, Jennifer J Westendorf, Sundeep Khosla, Merry Jo Oursler.   

Abstract

Under most conditions, resorbed bone is nearly precisely replaced in location and amount by new bone. Thus, it has long been recognized that bone loss through osteoclast-mediated bone resorption and bone replacement through osteoblast-mediated bone formation are tightly coupled processes. Abundant data conclusively demonstrate that osteoblasts direct osteoclast differentiation. Key questions remain, however, as to how osteoblasts are recruited to the resorption site and how the amount of bone produced is so precisely controlled. We hypothesized that osteoclasts play a crucial role in the promotion of bone formation. We found that osteoclast conditioned medium stimulates human mesenchymal stem (hMS) cell migration and differentiation toward the osteoblast lineage as measured by mineralized nodule formation in vitro. We identified candidate osteoclast-derived coupling factors using the Affymetrix microarray. We observed significant induction of sphingosine kinase 1 (SPHK1), which catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (S1P), in mature multinucleated osteoclasts as compared with preosteoclasts. S1P induces osteoblast precursor recruitment and promotes mature cell survival. Wnt10b and BMP6 also were significantly increased in mature osteoclasts, whereas sclerostin levels decreased during differentiation. Stimulation of hMS cell nodule formation by osteoclast conditioned media was attenuated by the Wnt antagonist Dkk1, a BMP6-neutralizing antibody, and by a S1P antagonist. BMP6 antibodies and the S1P antagonist, but not Dkk1, reduced osteoclast conditioned media-induced hMS chemokinesis. In summary, our findings indicate that osteoclasts may recruit osteoprogenitors to the site of bone remodeling through SIP and BMP6 and stimulate bone formation through increased activation of Wnt/BMP pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075223      PMCID: PMC2603259          DOI: 10.1073/pnas.0805133106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.

Authors:  Rutger L van Bezooijen; J Peter Svensson; Daniël Eefting; Annemieke Visser; Geertje van der Horst; Marcel Karperien; Paul H A Quax; Harry Vrieling; Socrates E Papapoulos; Peter ten Dijke; Clemens W G M Löwik
Journal:  J Bone Miner Res       Date:  2007-01       Impact factor: 6.741

Review 2.  Are nonresorbing osteoclasts sources of bone anabolic activity?

Authors:  Morten A Karsdal; Thomas J Martin; Jens Bollerslev; Claus Christiansen; Kim Henriksen
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

3.  Systemically administered bone morphogenetic protein-6 restores bone in aged ovariectomized rats by increasing bone formation and suppressing bone resorption.

Authors:  Petra Simic; Jasminka Buljan Culej; Iva Orlic; Lovorka Grgurevic; Natasa Draca; Radan Spaventi; Slobodan Vukicevic
Journal:  J Biol Chem       Date:  2006-06-23       Impact factor: 5.157

4.  Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.

Authors:  Chen Zhao; Naoko Irie; Yasunari Takada; Kouji Shimoda; Takeshi Miyamoto; Toru Nishiwaki; Toshio Suda; Koichi Matsuo
Journal:  Cell Metab       Date:  2006-08       Impact factor: 27.287

5.  Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling.

Authors:  Jiyoon Ryu; Hyung Joon Kim; Eun-Ju Chang; Hao Huang; Yoshiko Banno; Hong-Hee Kim
Journal:  EMBO J       Date:  2006-11-23       Impact factor: 11.598

6.  Impaired growth plate function in bmp-6 null mice.

Authors:  Mark J Perry; Kathleen E McDougall; Shu-Chen Hou; Jonathan H Tobias
Journal:  Bone       Date:  2007-10-04       Impact factor: 4.398

7.  Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone.

Authors:  Xu-Ming Dai; Xiao-Hua Zong; Mohammed P Akhter; E Richard Stanley
Journal:  J Bone Miner Res       Date:  2004-06-02       Impact factor: 6.741

8.  Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation.

Authors:  Christina N Bennett; Hongjiao Ouyang; Yanfei L Ma; Qingqiang Zeng; Isabelle Gerin; Kyle M Sousa; Timothy F Lane; Venkatesh Krishnan; Kurt D Hankenson; Ormond A MacDougald
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

9.  Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment.

Authors:  A Del Fattore; B Peruzzi; N Rucci; I Recchia; A Cappariello; M Longo; D Fortunati; P Ballanti; M Iacobini; M Luciani; R Devito; R Pinto; M Caniglia; E Lanino; C Messina; S Cesaro; C Letizia; G Bianchini; H Fryssira; P Grabowski; N Shaw; N Bishop; D Hughes; R P Kapur; H K Datta; A Taranta; R Fornari; S Migliaccio; A Teti
Journal:  J Med Genet       Date:  2005-08-23       Impact factor: 6.318

10.  Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.

Authors:  Debra L Ellies; Beth Viviano; John McCarthy; Jean-Philippe Rey; Nobue Itasaki; Scott Saunders; Robb Krumlauf
Journal:  J Bone Miner Res       Date:  2006-11       Impact factor: 6.741

View more
  187 in total

Review 1.  Cellular and molecular mechanisms of bone remodeling.

Authors:  Liza J Raggatt; Nicola C Partridge
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

Review 2.  Histone Deacetylases in Bone Development and Skeletal Disorders.

Authors:  Elizabeth W Bradley; Lomeli R Carpio; Andre J van Wijnen; Meghan E McGee-Lawrence; Jennifer J Westendorf
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

Review 3.  The role of osteoclast differentiation and function in skeletal homeostasis.

Authors:  Kyoji Ikeda; Sunao Takeshita
Journal:  J Biochem       Date:  2015-11-03       Impact factor: 3.387

4.  Association between sclerostin and bone density in chronic spinal cord injury.

Authors:  Leslie R Morse; Supreetha Sudhakar; Valery Danilack; Carlos Tun; Antonio Lazzari; David R Gagnon; Eric Garshick; Ricardo A Battaglino
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

Review 5.  Estrogen and the skeleton.

Authors:  Sundeep Khosla; Merry Jo Oursler; David G Monroe
Journal:  Trends Endocrinol Metab       Date:  2012-05-16       Impact factor: 12.015

Review 6.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

7.  Iron excess upregulates SPNS2 mRNA levels but reduces sphingosine-1-phosphate export in human osteoblastic MG-63 cells.

Authors:  L Peltier; C Bendavid; T Cavey; M-L Island; M Doyard; P Leroyer; C Allain; M De Tayrac; M Ropert; O Loréal; P Guggenbuhl
Journal:  Osteoporos Int       Date:  2018-05-03       Impact factor: 4.507

8.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

Authors:  Sutada Lotinun; Riku Kiviranta; Takuma Matsubara; Jorge A Alzate; Lynn Neff; Anja Lüth; Ilpo Koskivirta; Burkhard Kleuser; Jean Vacher; Eero Vuorio; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

9.  Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization.

Authors:  Kuniaki Ota; Patrick Quint; Ming Ruan; Larry Pederson; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

Review 10.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.